500 Skokie Boulevard
32 articles with Clarus Therapeutics
Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming A Publicly Listed Company To Address Unmet Needs Of Men And Women Through Development Of Androgen And Metabolic Therapies
Existing Clarus investors, led by H. I. G. Capital, will invest an additional $25 million in support of the company Transaction will accelerate commercialization of JATENZO®, the market-leading oral testosterone replacement therapy, and fund expansion of the company's pipeline of androgen and metabolic therapies for men and women, including orphan indications Clarus Therapeutics shareholders and Blue Water Acquisition Corp. shareholders will hold shares in Clarus Therapeutics
Clarus Therapeutics Presents Positive Safety And Efficacy Data For JATENZO® (Testosterone Undecanoate) Oral Capsules, CIII At ENDO 2021, The Endocrine Society's Annual Meeting
Data from a two-year study supports JATENZO as an effective long-term oral testosterone replacement therapy for hypogonadal men, maintaining normal testosterone levels with no evidence of liver toxicity
2/26/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Clarus Therapeutics Inc. announced today the appointment of Richard 'Ric' Peterson as chief financial officer (CFO). Peterson brings to Clarus a wealth of financial leadership experience from his 25-year career in the pharmaceutical industry, where he has served as CFO of public and private companies.
- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C. Bryson of the United States District Court of Delaware has postponed the February 8, 2021 jury trial scheduled to hear arguments in the patent litigation case of Lipo
Clarus Therapeutics, Inc. today announced that Express Scripts, Inc, one of the leading pharmacy benefit managers (PBMs) in the United States will now cover JATENZO® (testosterone undecanoate) capsules, CIII. JATENZO is the first and only FDA-approved oral testosterone undecanoate for testosterone
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
Clarus Therapeutics, Inc., a commercial men’s health specialty pharmaceutical company, announced today that it has completed a senior debt financing of up to $75M. Morgan Stanley & Co. LLC acted as sole placement agent for the transaction.
Lipocine Inc. announced that in an effort to streamline the issues and associated costs for dispute in its infringement lawsuit against Clarus Therapeutics, Inc. in the United States District Court related to the infringement of six Lipocine U.S. Patents by Clarus's JATENZO® product, Lipocine has voluntarily dismissed its allegations of patent infringement for expired U.S. Patent Nos. 6,569,463 and 6,923,988.
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
First and only FDA-approved oral treatment of its kind for testosterone deficiency 1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO ® (testosterone undecanoate) capsules, CIII is now available by prescription in the U.S. for the treatment of appropriate men with testosterone deficiency (hypogonadism). JATENZO is the first and only oral softgel testosterone undecanoate, and the first oral testosterone medicine approved by the U.S
12/13/2019Pharma and biotech companies strengthen their leadership teams and boards with this week's hires.
Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII
Clarus Therapeutics, Inc. announced the appointment of five senior leaders, each of whom bring valuable industry and category experience to the team.
Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction
Lipocine Inc. announced that the U.S. District Court of Delaware has set a trial date for Lipocine's patent infringement lawsuit against Clarus's JATENZO® drug product relating to six of Lipocine's U.S. patents.
Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
Today announced that it has filed suit against Clarus Therapeutics, Inc. in the United States District Court alleging that Clarus's JATENZO® product infringes six of Lipocine's U.S. patents
Clarus Therapeutics Provides Update On Patent Infringement Lawsuit Against Lipocine's Oral Product For Testosterone Replacement Therapy
Clarus Therapeutics Seeks Injunction Against The Marketing Of Lipocine Inc.'s Oral Product For Testosterone Replacement Therapy (LPCN 1021)
Clarus Therapeutics Expands Board of Directors With Appointment Of Two Pharmaceutical Industry Veterans